Cargando…

Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States

BACKGROUND: Recent attention to value frameworks has highlighted limitations of current conventional value and health technology assessment (V/HTA) methods (eg, cost-effectiveness). Multicriteria decision analysis (MCDA) has potential as a supplemental tool to incorporate additional value criteria i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendola, Nicholas D, Oehrlein, Elisabeth, Perfetto, Eleanor M, Westrich, Kimberly, McQueen, Robert Brett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372975/
https://www.ncbi.nlm.nih.gov/pubmed/36125060
http://dx.doi.org/10.18553/jmcp.2022.28.10.1190
_version_ 1785078465796505600
author Mendola, Nicholas D
Oehrlein, Elisabeth
Perfetto, Eleanor M
Westrich, Kimberly
McQueen, Robert Brett
author_facet Mendola, Nicholas D
Oehrlein, Elisabeth
Perfetto, Eleanor M
Westrich, Kimberly
McQueen, Robert Brett
author_sort Mendola, Nicholas D
collection PubMed
description BACKGROUND: Recent attention to value frameworks has highlighted limitations of current conventional value and health technology assessment (V/HTA) methods (eg, cost-effectiveness). Multicriteria decision analysis (MCDA) has potential as a supplemental tool to incorporate additional value criteria into conventional value assessment. OBJECTIVE: To conduct a pilot study to illustrate the impact of an MCDA approach on the value perceptions of hypothetical treatment profiles from a multistakeholder panel. METHODS: Participants voted on value perceptions of 2 hypothetical treatments with similar cost-effectiveness evidence: Treatment A for aggressive B-cell non-Hodgkin lymphoma in adults and treatment B for episodic migraine in adults. Participants voted treatments A and B as low, intermediate, or high value before and after a weighting exercise on prespecified, additional value criteria. Weights from participants were used to calculate treatment-specific MCDA scores from 0 (least favorable) to 100 (most favorable) and were presented to participants for a second value-perception vote. Analyses compared changes in value perceptions within treatments A and B post-MCDA exercise. RESULTS: Before considering MCDA scores for treatment A, 0% of participants considered it to be low, 52% intermediate, and 48% high value. After considering MCDA scores for treatment A, 4% considered it low, 29% intermediate, and 67% high value. Both before and after considering MCDA scores for treatment B, 13%, considered it low, 57% intermediate, and 30% high value. Mean MCDA scores for treatments A and B were 67 and 63, respectively. Of all stakeholders, 41% altered their perception of value for treatment A (9% negatively and 32% positively) and, separately, 45% for treatment B (23% both negatively and positively) after considering MCDA scores. CONCLUSIONS: With nearly half of participants altering their perception of value after consideration of additional value criteria, findings support the need for a more inclusive and flexible value assessment process.
format Online
Article
Text
id pubmed-10372975
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103729752023-07-31 Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States Mendola, Nicholas D Oehrlein, Elisabeth Perfetto, Eleanor M Westrich, Kimberly McQueen, Robert Brett J Manag Care Spec Pharm Research Brief BACKGROUND: Recent attention to value frameworks has highlighted limitations of current conventional value and health technology assessment (V/HTA) methods (eg, cost-effectiveness). Multicriteria decision analysis (MCDA) has potential as a supplemental tool to incorporate additional value criteria into conventional value assessment. OBJECTIVE: To conduct a pilot study to illustrate the impact of an MCDA approach on the value perceptions of hypothetical treatment profiles from a multistakeholder panel. METHODS: Participants voted on value perceptions of 2 hypothetical treatments with similar cost-effectiveness evidence: Treatment A for aggressive B-cell non-Hodgkin lymphoma in adults and treatment B for episodic migraine in adults. Participants voted treatments A and B as low, intermediate, or high value before and after a weighting exercise on prespecified, additional value criteria. Weights from participants were used to calculate treatment-specific MCDA scores from 0 (least favorable) to 100 (most favorable) and were presented to participants for a second value-perception vote. Analyses compared changes in value perceptions within treatments A and B post-MCDA exercise. RESULTS: Before considering MCDA scores for treatment A, 0% of participants considered it to be low, 52% intermediate, and 48% high value. After considering MCDA scores for treatment A, 4% considered it low, 29% intermediate, and 67% high value. Both before and after considering MCDA scores for treatment B, 13%, considered it low, 57% intermediate, and 30% high value. Mean MCDA scores for treatments A and B were 67 and 63, respectively. Of all stakeholders, 41% altered their perception of value for treatment A (9% negatively and 32% positively) and, separately, 45% for treatment B (23% both negatively and positively) after considering MCDA scores. CONCLUSIONS: With nearly half of participants altering their perception of value after consideration of additional value criteria, findings support the need for a more inclusive and flexible value assessment process. Academy of Managed Care Pharmacy 2022-10 /pmc/articles/PMC10372975/ /pubmed/36125060 http://dx.doi.org/10.18553/jmcp.2022.28.10.1190 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Brief
Mendola, Nicholas D
Oehrlein, Elisabeth
Perfetto, Eleanor M
Westrich, Kimberly
McQueen, Robert Brett
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
title Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
title_full Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
title_fullStr Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
title_full_unstemmed Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
title_short Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
title_sort stakeholder perception of pharmaceutical value: a multicriteria decision analysis pilot case study for value assessment in the united states
topic Research Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372975/
https://www.ncbi.nlm.nih.gov/pubmed/36125060
http://dx.doi.org/10.18553/jmcp.2022.28.10.1190
work_keys_str_mv AT mendolanicholasd stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates
AT oehrleinelisabeth stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates
AT perfettoeleanorm stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates
AT westrichkimberly stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates
AT mcqueenrobertbrett stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates